title: Combination therapy with ruxolitinib plus 5-azacytidine or continuous infusion of low dose cytarabine is feasible in patients with blast-phase myeloproliferative neoplasms.
authors.affiliation: Guy's and St. Thomas' NHS Foundation Trust, London , UK.
authors.forename: Anne
authors.initials: A
authors.lastname: Mwirigi
authors.forename: Sofia
authors.initials: S
authors.lastname: Galli
authors.forename: Clodagh
authors.initials: C
authors.lastname: Keohane
authors.forename: Kavita
authors.initials: K
authors.lastname: Raj
authors.forename: Deepti H
authors.initials: DH
authors.lastname: Radia
authors.forename: Claire N
authors.initials: CN
authors.lastname: Harrison
authors.forename: Donal P
authors.initials: DP
authors.lastname: McLornan
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001374:Azacitidine / Q000008:administration & dosage; D001752:Blast Crisis / Q000188:drug therapy*; D005260:Female; D019337:Hematologic Neoplasms / Q000188:drug therapy*; D006801:Humans; D008297:Male; D009196:Myeloproliferative Disorders / Q000188:drug therapy*; D009570:Nitriles; D011720:Pyrazoles / Q000008:administration & dosage; D011743:Pyrimidines
chemical_list: D009570:Nitriles; D011720:Pyrazoles; D011743:Pyrimidines; C540383:ruxolitinib; D001374:Azacitidine
keywords: Janus Kinase inhibitors; blast phase; hypomethylating agents; myeloproliferative neoplasms